GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

FEED · Mar 31, 2025

ENvue Medical, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001641172-25-011788General Corporate
Debt relative to revenueRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.debt_to_revenue

122.43% · OPTIONAL · NOT_ENOUGH_HISTORY

Capex intensity90thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.49% · OPTIONAL · VALID

Operating cash generation70thOwn-history percentile · N=10
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-131.02% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

11.29% · CORE · NOT_ENOUGH_HISTORY

Inventory pressure20thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

196.98% · OPTIONAL · VALID

Gross margin20thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.gross_margin

36.00% · CORE · VALID

Operating margin50thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.operating_margin

-180.68% · CORE · VALID

R&D intensity90thOwn-history percentile · N=10
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

51.71% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History16 statesHistory building
Sep 30, 20220/7 normalizedLevel 3Dec 31, 20220/7 normalizedLevel 3Mar 31, 20230/7 normalizedLevel 3Jun 30, 20230/7 normalizedLevel 3Sep 30, 20230/8 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/8 normalizedLevel 3Jun 30, 20240/8 normalizedLevel 3Sep 30, 20247/8 normalizedLevel 3Dec 31, 20247/8 normalizedLevel 3Mar 31, 20256/8 normalizedLevel 3Jun 30, 20256/7 normalizedLevel 3Sep 30, 20257/7 normalizedLevel 3Dec 31, 20257/7 normalizedLevel 3Mar 31, 20267/7 normalizedLevel 3Jun 30, 20267/7 normalizedLevel 3
Period transition

What moved in the state?

Capex Intensity Increased
Previous
0.12%
Current
0.49%
Delta
0.37%
Cash Generation Decreased
Previous
-98.36%
Current
-131.02%
Delta
-32.67%
Growth Decreased
Previous
12.05%
Current
11.29%
Delta
-0.75%
Inventory Pressure Increased
Previous
85.65%
Current
196.98%
Delta
111.32%
Margin Decreased
Previous
58.95%
Current
36.00%
Delta
-22.95%
Profitability Decreased
Previous
-140.03%
Current
-180.68%
Delta
-40.65%
R And D Intensity Increased
Previous
35.54%
Current
51.71%
Delta
16.17%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · FEED Fundamental State →Has State · ENvue Medical, Inc. →Transitioned To · FEED Fundamental State →Transitioned To · FEED CAPEX_INTENSITY_INCREASED →Transitioned To · FEED CASH_GENERATION_DECREASED →Transitioned To · FEED GROWTH_DECREASED →Transitioned To · FEED INVENTORY_PRESSURE_INCREASED →Transitioned To · FEED MARGIN_DECREASED →Transitioned To · FEED PROFITABILITY_DECREASED →Transitioned To · FEED R_AND_D_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.